Clinical

Dataset Information

0

SU5416 in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer

ABSTRACT: Phase II trial to study the effectiveness of SU5416 in treating patients who have metastatic or locally recurrent colorectal cancer. SU5416 may stop the growth of colorectal cancer by stopping blood flow to the tumor.

DISEASE(S): Colorectal Cancer,Colorectal Neoplasms

PROVIDER: 2005064 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Json Xml

Similar Datasets

Clinical Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas
| 2040104 | ecrin-mdr-crc
Clinical EMD 121974 in Treating Patients With Locally Advanced or Metastatic Cancer
| 2003668 | ecrin-mdr-crc
Clinical ZD 1839 Plus Combination Chemotherapy in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Colorectal Cancer
| 2006859 | ecrin-mdr-crc
Clinical Oxaliplatin With or Without Gefitinib in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer
| 2006855 | ecrin-mdr-crc
Clinical Rebeccamycin Analog in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer
| 2004187 | ecrin-mdr-crc
Clinical ISIS 2503 in Treating Patients With Metastatic and/or Locally Recurrent Colorectal Cancer
| 2003607 | ecrin-mdr-crc
Clinical Irinotecan and Cyclosporine in Treating Patients With Metastatic, Advanced or Locally Recurrent Colorectal Cancer
| 2003409 | ecrin-mdr-crc
Clinical Surgery With or Without Thalidomide in Treating Patients With Recurrent or Metastatic Colorectal Cancer
| 2006416 | ecrin-mdr-crc
Genomics RNAseq of paired primary and locally recurrent IDHwt GBM
| EGAS00001006871 | EGA
Transcriptomics CALGB 40603: Randomized Phase II 2 x 2 Factorial Trial of the Addition of Carboplatin +/- Bevacizumab to Neoadjuvant Weekly Paclitaxel Followed by Dose-Dense AC in Hormone Receptor-Poor/HER2-Negative Resectable Breast Cancer
2022-01-21 | GSE154524 | GEO